Prøve GULL - Gratis

FDA Cites Failure to Report GLP-1 Risks

The Wall Street Journal

March 11, 2026

Novo Nordisk said it is working quickly to respond to the FDA's request.

- BY ELIAS SCHISGALL

Novo Nordisk received a warning from the Food and Drug Administration for failing to report serious suspected side effects in patients who took the company's GLP-1 treatments.

Denne historien er fra March 11, 2026-utgaven av The Wall Street Journal.

Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.

Allerede abonnent? Logg på